查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1649459

電腦輔助藥物研發市場 - 2025-2030 年預測

Computer-Aided Drug Discovery Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

電腦輔助藥物發現市場預計將從 2025 年的 59.55 億美元成長到 2030 年的 103.06 億美元，預測期內的複合年成長率為 11.59%。

藥物研發是一個漫長而複雜的過程，但數位轉型正在使製藥業更有效率、更有效率。電腦輔助藥物發現、自動化數位化的整合對於提高品質、降低成本和縮短時間至關重要。動態在電腦輔助藥物發現的應用使得生物和化學系統的In Silico建模具有高度準確性，有助於識別新型候選藥物。慢性病的增加推動了快速藥物開發的需求，進一步推動了電腦輔助藥物發現市場的成長。根據美國國家衛生統計中心的數據，2023年美國將有1,958,310例新發癌症病例，609,820例死於癌症，因此迫切需要解決這個健康問題。

電腦輔助藥物發現市場促進因素：

  • 人工智慧在藥物研發的應用日益廣泛：尋找新藥十分複雜，耗時較長，需要先進的解決方案。確定能夠有效結合特定疾病相關標靶的合適化合物需要篩檢大量分子。人工智慧正在透過知識圖譜、In Silico目標識別和目標排序等技術發現潛在化合物，從而改變這一過程，促進更精準的治療方法的開發。

例如，2023年12月，默克推出了AIDDISON，這是一個整合生成式AI、機器學習和電腦輔助藥物設計的突破性藥物發現軟體平台。該軟體透過整合 Synthia™ 逆合成 API 彌合了虛擬分子設計與現實世界可製造性之間的差距。 AIDDISON 基於 20 多年藥物研發中累積的經過檢驗的資料集，根據藥物成功所必需的關鍵特性（如無毒性、溶解度和穩定性），分析了超過 600 億種可能性。像 AIDDISON 這樣的人工智慧和機器學習模型有可能顯著提高新藥的成功率，同時將與藥物研發相關的成本降低高達 70%。

影響電腦輔助藥物發現市場的地理趨勢：

  • 北美顯著成長：由於精神健康障礙盛行率上升、人工智慧技術的進步以及遠端醫療解決方案的接受度不斷提高等多種因素，預計美國的電腦輔助藥物發現市場將顯著成長。自 COVID-19 疫情加劇這些挑戰以來，對焦慮、憂鬱症和創傷後壓力症候群等心理健康問題的有效治療方案的需求激增。

隨著傳統醫療保健系統難以滿足需求，人工智慧技術正在成為提供可擴展、可存取的心理健康護理的可行解決方案。美國政府已經認知到人工智慧在醫療保健領域的潛力，並啟動了促進其發展的計劃。例如，美國人工智慧舉措旨在將美國定位為人工智慧領域的領先者，並正在製定人工智慧在各個領域的應用指南。此外，心理健康技術的豐厚融資機會正在吸引公共和私營部門的投資。強大的醫療保健IT基礎設施加上公眾對心理健康問題日益增強的認知，創造了一個有利於 AI 解決方案快速擴展的環境。摘要，由於人工智慧應用在藥物發現過程中的日益普及、全球對慢性病有效治療方法的需求不斷成長、政府支持措施促進醫療技術創新，以及有利的區域趨勢（尤其是北美）正在加強這一不斷擴大的市場環境，電腦輔助藥物發現市場將見證顯著成長。

為什麼要購買這份報告？

  • 深刻分析：獲得深入的市場洞察，涵蓋主要和新興地區，重點關注客戶群、政府政策和社會經濟因素、消費者偏好、垂直行業和其他子區隔。
  • 競爭格局：了解全球主要企業所採用的策略策略，並了解正確策略帶來的潛在市場滲透率。
  • 市場趨勢和促進因素：探索動態因素和關鍵市場趨勢以及它們將如何影響未來的市場發展。
  • 可行的建議：利用洞察力做出策略決策，在動態環境中開闢新的業務流和收益。
  • 適合廣泛用戶：對於新興企業、科學研究機構、顧問公司、中小企業和大型企業來說都是有益且具成本效益的。

它有什麼用途？

產業與市場考量、商業機會評估、產品需求預測、打入市場策略、地理擴張、資本支出決策、法律規範與影響、新產品開發、競爭影響

研究範圍

  • 2022 年至 2030 年的歷史資料與預測
  • 成長機會、挑戰、供應鏈前景、法規結構、客戶行為和趨勢分析
  • 競爭定位、策略和市場佔有率分析
  • 收益成長和預測分析包括國家在內的細分市場和地區
  • 公司概況（尤其是主要趨勢）

電腦輔助藥物發現市場區隔如下：

按類型

  • Structure-Based Drug Design
  • Ligand-Based Drug Design
  • Sequence-Based Approaches

按治療領域

  • 腫瘤學
  • 神經病學
  • 循環系統
  • 呼吸系統
  • 其他

按最終用途

  • 製藥公司
  • 生技公司
  • 研究所

按地區

  • 北美洲
  • 美國
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地區
  • 歐洲
  • 英國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲國家
  • 中東 中東和非洲
  • 沙烏地阿拉伯
  • UAE
  • 其他中東和非洲地區
  • 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 台灣
  • 泰國
  • 印尼
  • 其他亞太地區

目錄

第 1 章 簡介

  • 市場概況
  • 市場定義
  • 研究範圍
  • 市場區隔
  • 貨幣
  • 先決條件
  • 基準年和預測年時間表
  • 相關人員的主要利益

第2章調查方法

  • 研究設計
  • 研究過程
  • 資料檢驗

第3章執行摘要

  • 主要發現
  • 分析師觀點

第4章 市場動態

  • 市場促進因素
  • 市場限制
  • 波特五力分析
  • 產業價值鏈分析

5. 電腦輔助藥物發現市場（按類型）

  • 介紹
  • Structure-Based Drug Design
  • Ligand-Based Drug Design
  • Sequence-Based Approaches

6. 電腦輔助藥物發現市場（依治療領域）

  • 介紹
  • 腫瘤學
  • 神經病學
  • 循環系統
  • 呼吸系統
  • 其他

7. 電腦輔助藥物研發市場（依最終用途分類）

  • 介紹
  • 製藥公司
  • 生技公司
  • 研究所

8. 電腦輔助藥物發現市場（按地區）

  • 世界概況
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地區
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 其他中東和非洲地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他亞太地區

第9章競爭格局及分析

  • 主要企業和策略分析
  • 新興企業和市場盈利
  • 合併、收購、協議和合作
  • 競爭儀錶板

第10章 公司簡介

  • Aragen Life Sciences Pvt. Ltd.
  • Bioduro-Sundia
  • BOC Sciences
  • Aris Pharmaceuticals, Inc.
  • AstraZeneca
  • Schrodinger, Inc.
  • Bayer AG
  • Charles River Laboratories
  • Albany Molecular Research Inc.（Curia Global, Inc.）
  • Insilico Medicine
簡介目錄
Product Code: KSI061617235

The computer-aided drug discovery market is projected to grow at a CAGR of 11.59% over the forecast period, increasing from US$5.955 billion in 2025 to US$10.306 billion by 2030.

Drug discovery is a lengthy and complex process, but digital transformation is enhancing efficiency and effectiveness in the pharmaceutical industry. The integration of computer-aided drug discovery, automation, and digitization has become essential for improving quality, reducing costs, and shortening timelines. As resource constraints and changing scenarios arise, automation and digitization are key drivers of business growth.The application of quantum mechanics in computer-aided drug discovery has enabled highly accurate in-silico modeling of biological and chemical systems, facilitating the identification of novel drug candidates. The rising incidence of chronic diseases has intensified the need for rapid drug development, further boosting the growth of the computer-aided drug discovery market. According to the National Center for Health Statistics, it is projected that there will be 1,958,310 new cancer cases and 609,820 cancer deaths in the United States in 2023, underscoring the urgency of addressing these health challenges.

Drivers of the Computer-Aided Drug Discovery Market:

  • Expanding Use of Artificial Intelligence in Drug Discovery: The complexity and time-consuming nature of new drug discovery necessitate advanced solutions. Identifying suitable compounds that can effectively bind to specific disease-related targets requires screening vast numbers of molecules. AI is transforming this process by enabling the discovery of potential compounds through technologies such as knowledge graphs, in-silico target identification, and target ranking, which expedite treatment development with greater precision.

For instance, in December 2023, Merck launched AIDDISON, a groundbreaking drug discovery software platform that integrates generative AI, machine learning, and computer-aided drug design. This software bridges the gap between virtual molecule design and real-world manufacturability through Synthia(TM) retrosynthesis API integration. AIDDISON analyzes over 60 billion possibilities based on key properties essential for successful drugs-such as non-toxicity, solubility, and stability-drawing on more than two decades of validated datasets from pharmaceutical R&D.AI and machine learning models like AIDDISON significantly enhance the success rate of new patient therapies while potentially reducing costs associated with drug discovery by up to 70%.

Geographical Trends Shaping the Computer-Aided Drug Discovery Market:

  • Significant Growth in North America: The computer-aided drug discovery market is poised for substantial growth in the United States due to several factors, including a rising prevalence of mental health disorders, advancements in AI technologies, and increasing acceptance of telehealth solutions. The demand for effective treatment options for mental health issues such as anxiety, depression, and PTSD has surged since the COVID-19 pandemic exacerbated these challenges.

As traditional healthcare systems struggle to keep up with demand, AI technologies are emerging as viable solutions to provide scalable and accessible mental health care. AI-driven platforms can analyze large datasets to offer personalized therapy and real-time emotional support.The U.S. government has recognized AI's potential in healthcare and has initiated programs to promote its development. For example, the American AI Initiative aims to position the U.S. as a leader in artificial intelligence by establishing guidelines for its application across various sectors. Additionally, favorable funding opportunities for mental health technology have attracted investments from both public and private sectors.The combination of a robust healthcare IT infrastructure and growing public awareness about mental health issues creates an environment conducive to rapid expansion of AI solutions.In summary, the computer-aided drug discovery market is set for significant growth driven by increased adoption of AI applications in drug discovery processes, rising global demand for effective treatments for chronic diseases, supportive governmental initiatives promoting innovation in healthcare technologies, and favorable geographical trends-especially within North America-that enhance this expanding market landscape.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Computer-Aided Drug Discovery Market has been segmented as following:

By Type

  • Structure-Based Drug Design
  • Ligand-Based Drug Design
  • Sequence-Based Approaches

By Therapeutic Area

  • Oncology
  • Neurology
  • Cardiovascular Disease
  • Respiratory Disease
  • Others

By End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Research Laboratories

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Rest of South America
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Rest of the Middle East and Africa
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Taiwan
  • Thailand
  • Indonesia
  • Rest of Asia-Pacific

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process
  • 2.3. Data Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. COMPUTER-AIDED DRUG DISCOVERY MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Structure-Based Drug Design
  • 5.3. Ligand-Based Drug Design
  • 5.4. Sequence-Based Approaches

6. COMPUTER-AIDED DRUG DISCOVERY MARKET BY THERAPEUTIC AREA

  • 6.1. Introduction
  • 6.2. Oncology
  • 6.3. Neurology
  • 6.4. Cardiovascular Disease
  • 6.5. Respiratory Disease
  • 6.6. Others

7. COMPUTER-AIDED DRUG DISCOVERY MARKET BY END-USER

  • 7.1. Introduction
  • 7.2. Pharmaceutical Companies
  • 7.3. Biotechnology Companies
  • 7.4. Research Laboratories

8. COMPUTER-AIDED DRUG DISCOVERY MARKET BY GEOGRAPHY

  • 8.1. Global Overview
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Rest of South America
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Rest of Europe
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. United Arab Emirates
    • 8.5.3. Rest of the Middle East and Africa
  • 8.6. Asia-Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Taiwan
    • 8.6.6. Thailand
    • 8.6.7. Indonesia
    • 8.6.8. Rest of Asia-Pacific

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Aragen Life Sciences Pvt. Ltd.
  • 10.2. Bioduro-Sundia
  • 10.3. BOC Sciences
  • 10.4. Aris Pharmaceuticals, Inc.
  • 10.5. AstraZeneca
  • 10.6. Schrodinger, Inc.
  • 10.7. Bayer AG
  • 10.8. Charles River Laboratories
  • 10.9. Albany Molecular Research Inc. (Curia Global, Inc.)
  • 10.10. Insilico Medicine